


Claims

[Claim 1] A compound represented by Formula (I), a racemate of the compound, an enantiomer of the compound, a diastereomer of the compound, or a pharmaceutically acceptable salt of the compound, the racemate, the enantiomer, or the diastereomer:

[Formula (I)]



where R^1 is hydrogen, or C_{1-4} linear or branched alkyl;

R^2 is hydrogen, cyano, hydroxyl, C_{1-4} linear or branched alkyl, or C_{1-4} linear or branched alkoxy;

R^3 and R^4 are each independently hydrogen, halogen, cyano, C_{1-4} linear or branched alkoxy, or OR^8 ,

wherein R^8 is hydrogen, C_{3-10} heterocycloalkyl comprising 1-4 hetero atoms selected from the group consisting of N, O, and S, or alkyl substituted with C_{3-10} heterocycloalkyl comprising 1-4 hetero atoms selected from the group consisting of N, O, and S;

R^5 and R^6 are each independently hydrogen, halogen, cyano, halomethyl, hydroxyl, C_{1-4} linear or branched alkyl, or C_{1-4} linear or branched alkoxy;

Y is NH or O;

Z^1 and Z^2 are each independently CR^7 or N, wherein when Z^1 is N, Z^2 is CR^7 , and when Z^1 is CR^7 , Z^2 is N; and



W is CR^7 or N, wherein R^7 is hydrogen, halogen, cyano, hydroxyl, C_{1-4} linear or branched alkyl, or C_{1-4} linear or branched alkoxy.

[Claim 2] The compound, the racemate, the enantiomer, the diastereomer, or the pharmaceutically acceptable salt according to claim 1, wherein:

R^1 is hydrogen, or C_{1-4} linear or branched alkyl;

R^2 is hydrogen, or C_{1-4} linear or branched alkyl;

R^3 and R^4 are each independently hydrogen, halogen, cyano, C_{1-4} linear



R^5 and R^6 are each independently hydrogen, halogen, cyano, or C_{1-4} linear or branched alkoxy;

Y is NH or O;

Z^1 and Z^2 are each independently CR^7 or N, wherein when Z^1 is N, Z^2 is CR^7 , and when Z^1 is CR^7 , Z^2 is N; and


W is CR^7 or N, wherein R^7 is hydrogen or C_{1-2} linear alkyl.

[Claim 3] The compound, the racemate, the enantiomer, the diastereomer, or the pharmaceutically acceptable salt according to claim 2, wherein:

R^1 is hydrogen;

R^2 is hydrogen or C_{1-2} alkyl;

R^3 and R^4 are each independently hydrogen, C_{1-2} alkoxy,



R^5 and R^6 are each independently hydrogen, fluoro, cyano, or C_{1-2} linear alkoxy;

Y is NH or O;

Z¹ and Z² are each independently CR⁷ or N, wherein when Z¹ is N, Z² is CR⁷, and when Z¹ is CR⁷, Z² is N; and

W is CR⁷ or N, wherein R⁷ is selected from hydrogen or C₁₋₂ linear alkyl.

[Claim 4]

The compound according to claim 1, which is represented by:

(S)-3-(4-(((R)-4-(6-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)oxy)pyridin-3-yl)-7-fluoro-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(6-((3-methyloxetan-3-yl)methoxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-4-(6-(2-(1,1-dioxidothiomorpholino)ethoxy)pyridin-3-yl)-7-fluoro-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(6-(oxetan-3-yloxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(6-(((S)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(4-methyl-6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(2-methyl-6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-4-(5-chloro-6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-7-fluoro-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(5-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(4-methyl-6-((3-methyloxetan-3-yl)methoxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(2-methyl-6-((3-methyloxetan-3-yl)methoxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;

(S)-3-(4-(((R)-7-fluoro-4-(5-((3-methyloxetan-3-yl)methoxy)pyridin-2-yl)-

2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-7-fluoro-4-(5-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-7-fluoro-4-(5-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-5-cyano-4-(6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-4-(((R)-4-(5-chloro-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-7-fluoro-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-4-(5-cyano-6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-7-fluoro-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-4-(5-cyano-6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-7-fluoro-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-5-cyano-4-(6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-5-fluoro-4-(6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-5-methoxy-4-(6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-5-fluoro-4-(6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-5-methoxy-4-(6-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)phenyl)hex-4-ynoic acid;
 (S)-3-(4-(((R)-7-fluoro-4-(6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)amino)phenyl)hex-4-ynoic acid; or
 3-(6-(((R)-7-fluoro-4-(6-(((R)-tetrahydrofuran-3-yl)oxy)pyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)oxy)pyridin-3-yl)hex-4-ynoic acid,
 or a racemate of the compound, an enantiomer of the compound, a diastereomer of the compound, or a pharmaceutically acceptable salt of the compound, the racemate, the enantiomer, or the diastereomer.


[Claim 5] A pharmaceutical composition for use in the prevention or treatment of metabolic disorder, comprising the compound, the racemate, the enantiomer, the diastereomer, or the pharmaceutically acceptable salt according to any one claim of claims 1 to 4, wherein the metabolic disease is selected from the

group consisting of obesity, type 2 diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia and hypercholesterolemia.

[Claim 6] The pharmaceutical composition according to claim 5, further comprising a pharmaceutically acceptable excipient.

[Claim 7] Use of a compound represented by Formula (I), a racemate of the compound, an enantiomer of the compound, a diastereomer of the compound, or a pharmaceutically acceptable salt of the compound, the racemate, the enantiomer, or the diastereomer in the manufacture of a medicament for the prevention or treatment of metabolic disorder:

[Formula (I)]



where R^1 is hydrogen, or C_{1-4} linear or branched alkyl;

R^2 is hydrogen, cyano, hydroxyl, C_{1-4} linear or branched alkyl, or C_{1-4} linear or branched alkoxy;

R^3 and R^4 are each independently hydrogen, halogen, cyano, C_{1-4} linear or branched alkoxy, or OR^8 ,

wherein R^8 is hydrogen, C_{3-10} heterocycloalkyl comprising 1-4 hetero atoms selected from the group consisting of N, O, and S, or alkyl substituted with C_{3-10} heterocycloalkyl comprising 1-4 hetero atoms selected from the group consisting of N, O, and S;

R^5 and R^6 are each independently hydrogen, halogen, cyano, halomethyl, hydroxyl, C_{1-4} linear or branched alkyl, or C_{1-4} linear or branched alkoxy;

Y is NH or O;

Z^1 and Z^2 are each independently CR^7 or N, wherein when Z^1 is N, Z^2 is CR^7 ,

and when Z^1 is CR^7 , Z^2 is N; and
W is CR^7 or N, wherein R^7 is hydrogen, halogen, cyano, hydroxyl, C_{1-4} linear or branched alkyl, or C_{1-4} linear or branched alkoxy, wherein the metabolic disease is selected from the group consisting of obesity, type 2 diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia and hypercholesterolemia.